Business Wire
01 Oct 2026, 08:30 UTC · 1h ago
Verdict
Headline leans bullish. We score TEVA +0.60 across one claim.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.60strongly bullish
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Samsung Bioepis and Teva entered a global agreement for up to six potential biosimilar candidates, including SB41 (Fasenra) and SB44 (Ilaris).
Newannounced today
So whatAdding two confirmed candidates and four potential ones expands the pipeline for FY2027 revenue projections.
More positive than 87% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More positive than 78% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 78% of ticker scores this week
Teva entered a global agreement to develop and commercialize up to six potential biosimilar candidates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
36m ago
—
TEVA hasn't traded since this ran. Last close $39.60 (Sep 30); the reaction starts at the next open.
TEVA chart →
